Therapeutics for cognitive aging

Diana W. Shineman; Timothy A. Salthouse; Lenore J. Launer; Patrick R. Hof; George Bartzokis; Robin Kleiman; Victoria Luine; Jerry J. Buccafusco; Gary W. Small; Paul S. Aisen; David A. Lowe; Howard M. Fillit

doi:10.1111/j.1749-6632.2010.05532.x

Therapeutics for cognitive aging

Diana W. Shineman
, Timothy A. Salthouse
, Lenore J. Launer
, Patrick R. Hof
, George Bartzokis
, Robin Kleiman
, Victoria Luine
, Jerry J. Buccafusco
, Gary W. Small
, Paul S. Aisen
, David A. Lowe
, Howard M. Fillit

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

This review summarizes the scientific talks presented at the conference "Therapeutics for Cognitive Aging," hosted by the New York Academy of Sciences and the Alzheimer's Drug Discovery Foundation on May 15, 2009. Attended by scientists from industry and academia, as well as by a number of lay people - approximately 200 in all - the conference specifically tackled the many aspects of developing therapeutic interventions for cognitive impairment. Discussion also focused on how to define cognitive aging and whether it should be considered a treatable, tractable disease.

Original language	English
Pages (from-to)	E1-E15
Journal	Annals of the New York Academy of Sciences
Volume	1191
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1111/j.1749-6632.2010.05532.x
State	Published - Apr 2010

Access to Document

10.1111/j.1749-6632.2010.05532.x

Cite this

@article{7f15931c856c4fa99432408fbdeb9df4,

title = "Therapeutics for cognitive aging",

abstract = "This review summarizes the scientific talks presented at the conference {"}Therapeutics for Cognitive Aging,{"} hosted by the New York Academy of Sciences and the Alzheimer's Drug Discovery Foundation on May 15, 2009. Attended by scientists from industry and academia, as well as by a number of lay people - approximately 200 in all - the conference specifically tackled the many aspects of developing therapeutic interventions for cognitive impairment. Discussion also focused on how to define cognitive aging and whether it should be considered a treatable, tractable disease.",

author = "Shineman, \{Diana W.\} and Salthouse, \{Timothy A.\} and Launer, \{Lenore J.\} and Hof, \{Patrick R.\} and George Bartzokis and Robin Kleiman and Victoria Luine and Buccafusco, \{Jerry J.\} and Small, \{Gary W.\} and Aisen, \{Paul S.\} and Lowe, \{David A.\} and Fillit, \{Howard M.\}",

year = "2010",

month = apr,

doi = "10.1111/j.1749-6632.2010.05532.x",

language = "English",

volume = "1191",

pages = "E1--E15",

journal = " Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "John Wiley and Sons Inc.",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Therapeutics for cognitive aging

AU - Shineman, Diana W.

AU - Salthouse, Timothy A.

AU - Launer, Lenore J.

AU - Hof, Patrick R.

AU - Bartzokis, George

AU - Kleiman, Robin

AU - Luine, Victoria

AU - Buccafusco, Jerry J.

AU - Small, Gary W.

AU - Aisen, Paul S.

AU - Lowe, David A.

AU - Fillit, Howard M.

PY - 2010/4

Y1 - 2010/4

N2 - This review summarizes the scientific talks presented at the conference "Therapeutics for Cognitive Aging," hosted by the New York Academy of Sciences and the Alzheimer's Drug Discovery Foundation on May 15, 2009. Attended by scientists from industry and academia, as well as by a number of lay people - approximately 200 in all - the conference specifically tackled the many aspects of developing therapeutic interventions for cognitive impairment. Discussion also focused on how to define cognitive aging and whether it should be considered a treatable, tractable disease.

AB - This review summarizes the scientific talks presented at the conference "Therapeutics for Cognitive Aging," hosted by the New York Academy of Sciences and the Alzheimer's Drug Discovery Foundation on May 15, 2009. Attended by scientists from industry and academia, as well as by a number of lay people - approximately 200 in all - the conference specifically tackled the many aspects of developing therapeutic interventions for cognitive impairment. Discussion also focused on how to define cognitive aging and whether it should be considered a treatable, tractable disease.

UR - https://www.scopus.com/pages/publications/77952300518

U2 - 10.1111/j.1749-6632.2010.05532.x

DO - 10.1111/j.1749-6632.2010.05532.x

M3 - Review article

C2 - 20392284

AN - SCOPUS:77952300518

SN - 0077-8923

VL - 1191

SP - E1-E15

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

IS - SUPPL. 1

ER -

Therapeutics for cognitive aging

Abstract

Access to Document

Fingerprint

Cite this